Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 6:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 1,335 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: NaCl-saline placebo Clear all
Terminated Phase 4 Interventional

Nebulized Heparin for the Treatment of COVID-19 Induced Lung Injury

NCT04397510
View directory record Official record
Conditions
Covid-19, ARDS, Human, Acute Lung Injury
Interventions
Heparin, 0.9% Sodium-chloride
Drug
Lead sponsor
Frederick Health
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Frederick, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Oct 14, 2026, 6:23 AM EDT
Completed Phase 4 Interventional Results available

Intraoperative Infusion of Precedex to Reduce Length of Stay After Lumbar Spine Fusion

NCT00808665
View directory record Official record
Conditions
Spinal Fusion Acquired, Spinal Stenosis, Lesions of Lumbosacral Intervertebral Disc, Spinal Diseases
Interventions
Dexmedetomidine, 0.9% Saline
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 25, 2018 · Synced Oct 14, 2026, 6:23 AM EDT
Terminated Phase 4 Interventional Results available

Steroid Administration for Articular Fractures of the Elbow (SAFE Trial)

NCT04738318
View directory record Official record
Conditions
Elbow Fracture
Interventions
Glucocorticoids, Saline
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 29, 2023 · Synced Oct 14, 2026, 6:23 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Oxytocin and Pain Sensitivity and Threshold

NCT01988649
View directory record Official record
Conditions
Pain
Interventions
Intranasal Oxytocin, Placebo (saline)
Drug
Lead sponsor
Northwestern University
Other
Eligibility
20 Years to 35 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Oct 14, 2026, 6:23 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)

NCT07266558
View directory record Official record
Conditions
SARS-CoV-2
Interventions
mRNA-1273, mRNA-1283, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
50 Years to 64 Years
Enrollment
30,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
150
States / cities
Birmingham, Alabama • Cullman, Alabama • Mobile, Alabama + 127 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 14, 2026, 6:23 AM EDT
Completed Phase 1 Interventional Results available

Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus

NCT01673178
View directory record Official record
Conditions
Diabetes Melliuts, Type 2
Interventions
Placebo, 25 mg PF-05231023, 50 mg PF-05231023, 100 mg PF-05231023, 150 mg PF-05231023
Other · Drug
Lead sponsor
Pfizer
Industry
Eligibility
30 Years to 70 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
17
States / cities
Anaheim, California • Chula Vista, California • Walnut Creek, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2015 · Synced Oct 14, 2026, 6:23 AM EDT
Suspended Phase 3 Interventional

Ketorolac Applied by Continuous IV Infusion for Treatment of Moderately Severe Postoperative Pain Following Bunionectomy

NCT05324358
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Ketorolac Tromethamine, Morphine Sulfate, Intravenous Placebo for NTM-001, IV Placebo for Morphine
Drug · Other
Lead sponsor
Neumentum, Inc.
Other
Eligibility
18 Years to 64 Years
Enrollment
341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
10
States / cities
Sun City, Arizona • Bakersfield, California • Canoga Park, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 14, 2026, 6:23 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Lidocaine For Treatment of Post-operative Pain From Donor Sites Following Burn Injury.

NCT02229578
View directory record Official record
Conditions
Pain
Interventions
Lidocaine, Placebo
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
2
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 1, 2024 · Synced Oct 14, 2026, 6:23 AM EDT
Completed Phase 3 Interventional Results available

Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Telangiectasia Patients

NCT02770807
View directory record Official record
Conditions
Nervous System Disease, Genetic Syndrome
Interventions
EryDex Low dose DSP, EryDex High dose DSP, Pooled Placebo
Drug
Lead sponsor
Quince Therapeutics S.p.A.
Industry
Eligibility
6 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
4
States / cities
Los Angeles, California • Baltimore, Maryland • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated May 10, 2024 · Synced Oct 14, 2026, 6:23 AM EDT
Terminated Phase 2 Interventional Results available

Phase IIb Study of IFN-K in Systemic Lupus Erythematosus

NCT02665364
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
IFNα-Kinoid, Placebo, ISA 51 VG
Biological · Other
Lead sponsor
Neovacs
Industry
Eligibility
18 Years to 65 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
13
States / cities
Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2020 · Synced Oct 14, 2026, 6:23 AM EDT
Completed Not applicable Interventional Results available

Safety and Effectiveness of Monovisc® Injection for Osteoarthritis of the Knee

NCT00653432
View directory record Official record
Conditions
Osteoarthritis
Interventions
Monovisc®, Saline
Device · Other
Lead sponsor
Anika Therapeutics, Inc.
Industry
Eligibility
35 Years to 75 Years
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
30
States / cities
Hoover, Alabama • Mesa, Arizona • Phoenix, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2023 · Synced Oct 14, 2026, 6:23 AM EDT
Terminated Phase 2 Interventional Results available

Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa

NCT01838499
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
MEDI8968, Saline
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
27
States / cities
Phoenix, Arizona • Bakersfield, California • Fremont, California + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2016 · Synced Oct 14, 2026, 6:23 AM EDT
Completed Phase 2 Interventional

A Clinical Study of NLY01 in Patient's With Early Parkinson's Disease

NCT04154072
View directory record Official record
Conditions
Parkinson Disease
Interventions
NLY01, Vehicle
Drug
Lead sponsor
Neuraly, Inc.
Industry
Eligibility
30 Years to 80 Years
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
60
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 14, 2026, 6:23 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Belcesiran in Patients With AATLD

NCT04764448
View directory record Official record
Conditions
Alpha 1-Antitrypsin Deficiency
Interventions
Belcesiran, Placebo
Drug · Other
Lead sponsor
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
La Jolla, California • Gainesville, Florida • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 14, 2026, 6:23 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

A Study of the Efficacy of Subcutaneous Phosphatidylcholine and Deoxycholate Injections for Localized Fat Removal

NCT00851747
View directory record Official record
Conditions
Obesity
Interventions
Phosphatidylcholine Deoxycholate, Saline
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
25 Years to 70 Years · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Oct 14, 2026, 6:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Intake and Intra-Nasal Insulin for African American Adults (FIINAAL)

NCT04739371
View directory record Official record
Conditions
Insulin
Interventions
Insulin, Regular, Human, Placebo
Drug
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
45 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Oct 14, 2026, 6:23 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age

NCT05992935
View directory record Official record
Conditions
Norovirus Acute Gastroenteritis
Interventions
mRNA-1403, mRNA-1405, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,407 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
14
States / cities
Long Beach, California • Longmont, Colorado • Hollywood, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 14, 2026, 6:23 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

NCT05645107
View directory record Official record
Conditions
Hypogammaglobulinemia, Bacterial Infections, B-cell Chronic Lymphocytic Leukemia, Multiple Myleoma, Non-Hodgkin Lymphoma
Interventions
Xembify, Placebo
Drug
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
9
States / cities
Bullhead City, Arizona • Huntington Park, California • St. Petersburg, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 14, 2026, 6:23 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study on the Reactogenicity, Safety and Immune Response of a Vaccine Against Herpes Simplex Virus (HSV)-2 in Healthy Participants Aged 18-40 Years

NCT04762511
View directory record Official record
Conditions
Herpes Simplex
Interventions
Lower dose formulation of HSV vaccine (GSK4108771A), Low dose formulation of HSV vaccine (GSK4108771A), Medium dose formulation of HSV vaccine (GSK4108771A), High dose formulation of HSV vaccine (GSK4108771A), Placebo (saline)
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 40 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
2
States / cities
Lenexa, Kansas • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 28, 2021 · Synced Oct 14, 2026, 6:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

ZIKA Vaccine in Naive Subjects

NCT02952833
View directory record Official record
Conditions
Zika Virus Infection
Interventions
Saline, Zika Virus Purified Inactivated Vaccine (ZPIV)
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
91 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Oct 14, 2026, 6:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647

NCT05105048
View directory record Official record
Conditions
Cytomegalovirus Infection
Interventions
mRNA-1647, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
3
States / cities
North Hollywood, California • San Diego, California • Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Sep 11, 2023 · Synced Oct 14, 2026, 6:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety Study of Hepatitis E Vaccine (HEV239)

NCT03827395
View directory record Official record
Conditions
Hepatitis E, Immunisation
Interventions
HEV 239, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 24, 2021 · Synced Oct 14, 2026, 6:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluate the Safety, Tolerability and PK of HF1K16 in Healthy Volunteers

NCT05386823
View directory record Official record
Conditions
Healthy
Interventions
HF1K16, Placebo
Drug
Lead sponsor
HighField Biopharmaceuticals Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated May 23, 2024 · Synced Oct 14, 2026, 6:23 AM EDT
Completed Phase 2 Interventional Results available

Botulinum Toxin A to Treat Arm Tremor

NCT02207946
View directory record Official record
Conditions
Essential Tremor of the Upper Limbs
Interventions
IncobotulinumtoxinA, Placebo
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 14, 2026, 6:23 AM EDT